 "Zydus Lifesciences")
The drug will likely be manufactured at Zydus’ formulation manufacturing facility in Moraiya, Ahmedabad.
Zydus Lifesciences on Thursday stated it has obtained approval from the US well being regulator to market a generic product to deal with zits within the American market.
The drug agency has obtained ultimate approval from the US Meals and Drug Administration (USFDA) for Isotretinoin Capsules USP (10 mg, 20 mg 30 mg and 40 mg), it stated in an announcement.
Isotretinoin capsules are used to deal with extreme cystic zits that has not responded to different remedies.
The drug will likely be manufactured at Zydus’ formulation manufacturing facility in Moraiya, Ahmedabad.
As per the IQVIA MAT information, Isotretinoin Capsules had annual gross sales of USD 165 million within the US.
Shares of Zydus Lifesciences had been buying and selling 0.13 per cent down at Rs 627.35 apiece on the BSE.
(Solely the headline and movie of this report could have been reworked by the Enterprise Normal workers; the remainder of the content material is auto-generated from a syndicated feed.)
First Printed: Aug 31 2023 | 4:36 PM IST
